866-997-4948(US-Canada Toll Free)

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Published By :

GBI Research

Published Date : Nov 2011

Category :

Therapeutic Area

No. of Pages : 230 Pages


GBI Research, the leading business intelligence provider, has released its latest research Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. 

The report provides an in-depth analysis of the major CNS disorder including Alzheimers disease, multiple sclerosis, Parkinsons disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. 

In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market. 

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimers disease, multiple sclerosis, Parkinsons disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. 

The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. 

The market for Alzheimer\'s disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

Scope

  • Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 12

2 CNS Disorder Therapeutic Market to 2017 - Introduction 15
2.1 GBI Research Report Guidance 15

3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16
3.1 Introduction 16
3.2 Revenue 17
3.2.1 Generic Share 18
3.2.2 Annual Cost of Treatment 19
3.3 Top CNS Drug Products 20
3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20
3.3.2 Zyprexa (olanzapine) 20
3.3.3 Cymbalta (duloxetine Hcl) 21
3.3.4 Copaxone (glatiramer acetate) 21
3.3.5 Lyrica (pregabalin) 22
3.3.6 Abilify (aripiprazole) 22
3.3.7 Avonex (Interferon beta-1a) 23
3.3.8 Rebif (interferon beta-1a) 23
3.3.9 Effexor (venlafaxine) 23
3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24

4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25
4.1 Revenue Analysis by Geography 25
4.2 The US 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Treatment 27
4.3 Top Five Countries of Europe 28
4.3.1 Revenue 28
4.3.2 Annual Cost of Treatment 30
4.4 Japan 31
4.4.1 Revenue 31
4.4.2 Annual Cost of Treatment 32

5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33
5.1 Alzheimer\'s Disease 33
5.1.1 Introduction 33
5.1.2 Revenue 35
5.1.3 Annual Cost of Treatment 39
5.1.4 Treatment Usage Patterns 40
5.2 Drivers and Restraints to Alzheimer\'s Disease Market 42
5.2.1 Drivers for Alzheimer\'s disease Market 42
5.2.2 Restraints for Alzheimer\'s disease Market 43
5.3 Attention Deficit Hyperactivity Disorder (ADHD) 43
5.3.1 Introduction 43
5.3.2 Revenue 45
5.3.3 Annual Cost of Treatment 49
5.3.4 Treatment Usage Patterns 50
5.4 Drivers and Barriers to ADHD Market 52
5.4.1 Drivers for ADHD Market 52
5.4.2 Barriers for ADHD Market 52
5.5 Bipolar Disorder 53
5.5.1 Introduction 53
5.5.2 Revenue 55
5.5.3 Annual Cost of Treatment 58
5.5.4 Treatment Usage Patterns 59
5.6 Drivers and Barriers to Bipolar Disorder Market 61
5.6.1 Drivers for Bipolar Disorder Market 61
5.6.2 Barriers for Bipolar Disorder Market 61
5.7 Diabetic Neuropathy 62
5.7.1 Introduction 62
5.7.2 Revenue 64
5.7.3 Annual Cost of Treatment 67
5.7.4 Treatment Usage Pattern 68
5.8 Drivers and Restraints to Diabetic Neuropathy Market 70
5.8.1 Drivers for Diabetic Neuropathy Market 70
5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 70
5.9 Epilepsy 71
5.9.1 Introduction 71
5.9.2 Revenue 72
5.9.3 Annual Cost of Treatment 75
5.9.4 Treatment Usage Patterns 76
5.10 Drivers and Barriers to Epilepsy Market 78
5.10.1 Drivers for Epilepsy Market 78
5.10.2 Barriers to Epilepsy Market 78
5.11 Insomnia 79
5.11.1 Introduction 79
5.11.2 Revenue 81
5.11.3 Annual Cost of Treatment 84
5.11.4 Treatment Usage Patterns 85
5.12 Drivers and Barriers to Insomnia Market 87
5.12.1 Drivers for Insomnia Market 87
5.12.2 Barriers for Insomnia Market 88
5.13 Migraine 88
5.13.1 Introduction 88
5.13.2 Revenue 90
5.13.3 Annual Cost of Treatment 94
5.13.4 Treatment Usage Patterns 95
5.14 Drivers and Barriers for Migraine Market 98
5.14.1 Drivers for Migraine Market 98
5.14.2 Barriers for Migraine Market 99
5.15 Multiple Sclerosis 99
5.15.1 Introduction 99
5.15.2 Revenue 102
5.15.3 Annual Cost of Treatment 106
5.15.4 Treatment Usage Patterns 107
5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market 109
5.16.1 Drivers for Multiple Sclerosis Market 109
5.16.2 Restraints for Multiple Sclerosis Market 110
5.17 Parkinsons Disease 110
5.17.1 Introduction 110
5.17.2 Revenue 112
5.17.3 Annual Cost of Treatment 115
5.17.4 Treatment Usage Patterns 116
5.18 Drivers and Restraints to Parkinsons Disease Therapeutics Market 118
5.18.1 Drivers for the Parkinsons disease Therapeutics Market 118
5.18.2 Restraints for the Parkinsons disease Therapeutics Market 118
5.19 Schizophrenia 119
5.19.1 Introduction 119
5.19.2 Revenue 121
5.19.3 Annual Cost of Treatment 124
5.19.4 Treatment Usage Pattern 125
5.20 Drivers and Barriers to Schizophrenia Market 127
5.20.1 Drivers for Schizophrenia Market 127
5.20.2 Barriers for Schizophrenia Market 128
5.21 Major Depressive Disorder (MDD) 128
5.21.1 Introduction 128
5.21.2 Revenue 130
5.21.3 Annual Cost of Treatment 133
5.21.4 Treatment Usage Patterns 134
5.22 Drivers and Barriers to MDD Market 136
5.22.1 Drivers for MDD Market 136
5.22.2 Barriers for MDD Market 136

6 Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 138
6.1 Introduction 138
6.1.1 Product Pipeline by Indication 138
6.1.2 Product Pipeline by Clinical Stage of Development 139
6.2 Alzheimer\'s disease 140
6.2.1 Introduction 140
6.3 Attention Deficit Hyperactivity Disorder (ADHD) 150
6.3.1 Introduction 150
6.4 Bipolar Disorder 153
6.4.1 Introduction 153
6.5 Diabetic Neuropathy 155
6.5.1 Introduction 155
6.6 Epilepsy 157
6.6.1 Introduction 157
6.7 Insomnia 161
6.7.1 Introduction 161
6.8 Major Depressive Disorder (MDD) 163
6.8.1 Introduction 163
6.9 Migraine 167
6.9.1 Introduction 167
6.10 Multiple Sclerosis 169
6.10.1 Introduction 169
6.11 Parkinson\'s Disease 175
6.11.1 Introduction 175
6.12 Schizophrenia 182
6.12.1 Introduction 182
6.13 NDA Filed Molecules 186
6.13.1 Alzheimer\'s disease 186
6.13.2 Bipolar Disorder 187
6.13.3 Epilepsy 189
6.13.4 Insomnia 191
6.13.5 MDD 193
6.13.6 Migraine 194
6.13.7 Parkinsons disease 195
6.13.8 Multiple sclerosis 195

7 CNS Disorder Therapeutic Market to 2017 - Competitive Landscape 198
7.1 Market Share Analysis 198
7.1.1 Eli Lilly 199
7.1.2 Pfizer 200
7.1.3 AstraZeneca 201
7.1.4 Johnson & Johnson (J&J) 202
7.1.5 Teva 203

8 CNS Disorder Therapeutic Market to 2017 - M&A Landscape 204

8.1 M&A Deals (2010-2011) 204
8.1.1 M&A Deals by Region 204
8.1.2 M&A Deals by Indication 205
8.1.3 M&A Deals by Value 206
8.1.4 Deal Summary of M&A Deals by Value 209
8.2 Licensing Deals 212
8.2.1 Deal Summary 216
8.3 Co-development Deals 218
8.3.1 Deal Summary 220

9 CNS Disorder Therapeutic Market to 2017 - Appendix 223
9.1 Market Definitions 223
9.2 Abbreviations 223
9.3 Research Methodology 224
9.3.1 Coverage 224
9.3.2 Secondary Research 225
9.3.3 Primary Research 225
9.3.4 Therapeutic Landscape 226
9.3.5 Geographical Landscape 229
9.3.6 Pipeline Analysis 229
9.3.7 Competitive Landscape 229
9.3.8 Expert Panel Validation 229
9.4 Contact Us 229
9.5 Disclaimer 229
9.6 Sources 230

List of Table


Table 1: CNS Disorder Therapeutic Market, Global, Revenue ($bn), 2002-2010 17
Table 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2010-2017 17
Table 3: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2010 18
Table 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2010-2017 18
Table 5: CNS Disorder Therapeutic Market, The US, Revenue ($m), 2002-2010 25
Table 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast($m), 2010-2017 25
Table 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2010 26
Table 8: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2010-2017 26
Table 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 28
Table 10: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 28
Table 11: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 29
Table 12: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 29
Table 13: CNS Disorder Therapeutic Market, Japan, Revenue ($m), 2002-2010 30
Table 14: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2010-2017 30
Table 15: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2010 31
Table 16: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2010-2017 31
Table 17: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, FDA Approved Cholinesterase Inhibitors, 2010 33
Table 18: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Revenue ($bn), 2002-2010 34
Table 19: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Revenue Forecast ($bn), 2010-2017 34
Table 20: CNS Disorder Therapeutics Market, Alzheimer\'s Disease, Revenue by Country ($m), 2002-2010 36
Table 21: CNS Disorder Therapeutics Market, Alzheimer\'s Disease, Revenue by Country ($m), 2010-2017 36
Table 22: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Annual Cost of Treatment ($), 2002-2010 38
Table 23: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Annual Cost of Treatment ($), 2010-2017 38
Table 24: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 39
Table 25: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 40
Table 26: CNS Disorder Therapeutic Market, ADHD, Global Revenue ($m), 2002-2010 45
Table 27: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2010-2017 45
Table 28: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2010 46
Table 29: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2010-2017 46
Table 30: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2010 48
Table 31: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2010-2017 48
Table 32: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2010 49
Table 33: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2010-2017 50
Table 34: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue ($m), 2002-2010 54
Table 35: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2010-2017 54
Table 36: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2010 55
Table 37: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2010-2017 56
Table 38: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 57
Table 39: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 57
Table 40: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2010 58
Table 41: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2010-2017 59
Table 42: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010 63
Table 43: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast($m), 2010-2017 63
Table 44: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010 64
Table 45: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017 65
Table 46: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010 66
Table 47: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017 66
Table 48: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010 67
Table 49: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017 68
Table 50: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue ($m), 2002-2010 71
Table 51: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2010-2017 71
Table 52: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2002-2010 72
Table 53: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2010-2017 73
Table 54: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2010 74
Table 55: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2010-2017 74
Table 56: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2010 75
Table 57: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2010-2017 76
Table 58: CNS Disorder Therapeutic Market, Insomnia, Global Revenue ($m), 2002-2010 80
Table 59: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast($m), 2010-2017 80
Table 60: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2010 81
Table 61: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2010-2017 82
Table 62: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2010 83
Table 63: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2010-2017 83
Table 64: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2010 84
Table 65: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2010-2017 85
Table 66: CNS Disorder Therapeutic Market, Migraine, Global Revenue ($m), 2002-2010 89
Table 67: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast($m), 2010-2017 90
Table 68: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2002-2010 91
Table 69: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2010-2017 91
Table 70: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2010 93
Table 71: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2010-2017 93
Table 72: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2010 95
Table 73: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2010-2017 95
Table 74: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010 102
Table 75: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2010-2017 102
Table 76: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010 103
Table 77: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017 104
Table 78: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010 105
Table 79: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017 105
Table 80: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010 106
Table 81: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017 107
Table 82: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Global Revenue ($m), 2002-2010 111
Table 83: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Global Revenue Forecast ($m), 2010-2017 111
Table 84: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Revenue by Country ($m), 2002-2010 112
Table 85: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Revenue by Country ($m), 2010-2017 113
Table 86: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Annual Cost of Treatment ($), 2002-2010 114
Table 87: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Annual Cost of Treatment ($), 2010-2017 114
Table 88: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 115
Table 89: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 116
Table 90: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue ($m), 2002-2010 120
Table 91: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2010-2017 120
Table 92: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2010 121
Table 93: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2010-2017 122
Table 94: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 123
Table 95: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 123
Table 96: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2010 124
Table 97: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2010-2017 125
Table 98: CNS Disorder Therapeutic Market, MDD, Global Revenue ($m), 2002-2010 129
Table 99: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast ($m), 2010-2017 130
Table 100: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2010 130
Table 101: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2010-2017 131
Table 102: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2010 132
Table 103: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2010-2017 132
Table 104: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2002-2010 133
Table 105: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2010-2017 134
Table 106: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Discovery Product Pipeline, 2011 140
Table 107: CNS Disorder Therapeutic Market, ADHD Product Pipeline, 2011 150
Table 108: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline, 2011 153
Table 109: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline, 2011 155
Table 110: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline, 2011 157
Table 111: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline, 2011 161
Table 112: CNS Disorder Therapeutic Market, MDD, Product Pipeline, 2011 163
Table 113: CNS Disorder Therapeutic Market, Migraine, Product Pipeline, 2011 167
Table 114: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline, 2011 169
Table 115: CNS Disorder Therapeutic Market, Parkinson\'s Disease, Product Pipeline, 2011 175
Table 116: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline, 2011 182
Table 117: CNS Disorder Therapeutic Market, Global, M&A Deals ($m), 2010-2011 206
Table 118: CNS Disorder Therapeutic Market, Global, Announced M&A Deals ($m), 2010-2011 207
Table 119: CNS Disorder Therapeutic Market, Global, Licensing Deals ($m), 2010-2011 212
Table 120: CNS Disorder Therapeutic Market, Co-developments, 2010-2011 218

List of Chart


Figure 1: CNS Disorder Therapeutic Market, Global, Revenue Share by Indication (%), 2010 16
Figure 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017 17
Figure 3: CNS Disorder Therapeutic Market, Global, Generic Share (%), 2010 and 2017 18
Figure 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2017 19
Figure 5: CNS Disorder Therapeutic Market, Revenue by Geography (%),2010 25
Figure 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast ($m), 2002-2017 26
Figure 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2017 27
Figure 8: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 28
Figure 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 30
Figure 10: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2002-2017 31
Figure 11: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2017 32
Figure 12: CNS Disorder Therapeutic Market, Alzheimer\'s Disease Treatment Algorithm 34
Figure 13: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Revenue Forecast ($bn), 2002-2017 35
Figure 14: CNS Disorder Therapeutics Market, Alzheimer\'s Disease, Revenue by Country ($m), 2002-2017 36
Figure 15: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Generic Share in Alzheimers Disease Market, 2010 and 2017 38
Figure 16: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Annual Cost of Treatment ($), 2002-2017 39
Figure 17: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 40
Figure 18:CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Global Market Drivers and Restraints, 2010-2017 42
Figure 19: CNS Disorder Therapeutic Market, ADHD Treatment Algorithm 44
Figure 20: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2002-2017 46
Figure 21: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2017 47
Figure 22: CNS Disorder Therapeutic Market, ADHD, Generic Share in ADHD Market, 2010 and 2017 48
Figure 23: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2017 49
Figure 24: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2017 50
Figure 25: CNS Disorder Therapeutic Market, ADHD, Global Market Drivers and Barriers, 2010-2017 52
Figure 26: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 54
Figure 27: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2002-2017 55
Figure 28: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2017 56
Figure 29: CNS Disorder Therapeutic Market, Bipolar Disorder, Generic Share in Bipolar Disorder Market, 2010 and 2017 57
Figure 30: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 58
Figure 31: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2017 59
Figure 32: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 61
Figure 33: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 63
Figure 34: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast ($m), 2002-2017 64
Figure 35: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017 65
Figure 36: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market ($m), 2010 and 2017 66
Figure 37: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017 67
Figure 38: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017 68
Figure 39: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017 70
Figure 40: CNS Disorder Therapeutic Market, Epilepsy, Treatment Algorithm 71
Figure 41: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2002-2017 72
Figure 42: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m),2002-2017 73
Figure 43: CNS Disorder Therapeutic Market, Epilepsy, Generic Share in Epilepsy Market, 2010 and 2017 74
Figure 44: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2017 75
Figure 45: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2017 76
Figure 46: CNS Disorder Therapeutic Market, Epilepsy, Global Market Drivers and Barriers, 2010-2017 78
Figure 47: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 80
Figure 48: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast ($m), 2002-2017 81
Figure 49: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2017 82
Figure 50: CNS Disorder Therapeutic Market, Insomnia, Generic Share in Insomnia Market, 2010 and 2017 83
Figure 51: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2017 84
Figure 52: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2017 85
Figure 53: CNS Disorder Therapeutic Market, Insomnia, Global Market Drivers and Barriers, 2010-2017 87
Figure 54: CNS Disorder Therapeutic Market, Migraine, Treatment Algorithm 89
Figure 55: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast ($m), 2002-2017 90
Figure 56: CNS Disorder Therapeutic Market, Mirgaine, Revenue by Country ($m), 2002-2017 91
Figure 57: CNS Disorder Therapeutic Market, Migraine, Generic Share in Migraine Market, 2010 and 2017 93
Figure 58: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2017 94
Figure 59: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2017 95
Figure 60: CNS Disorder Therapeutic Market, Migraine, Global Market Drivers and Barriers, 2010-2017 98
Figure 61: CNS Disorder Therapeutic Market, Multiple Sclerosis (RRMS), Treatment Algorithm 101
Figure 62:CNS Disorder Therapeutic Market, Multiple Sclerosis (PRMS), Treatment Algorithm 102
Figure 63: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2002-217 103
Figure 64: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017 104
Figure 65: CNS Disorder Therapeutic Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, 2010 and 2017 105
Figure 66: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017 106
Figure 67: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017 107
Figure 68: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 109
Figure 69: CNS Disorder Therapeutic Market, Parkinsons Disease, Treatment Algorithm 111
Figure 70: CNS Disorder Therapeutic Market, Parkinsons Disease, Global Revenue Forecast($m), 2002-2017 112
Figure 71: CNS Disorder Therapeutic Market, Parkinsons Disease, Revenue by Country ($m), 2002-2017 113
Figure 72: CNS Disorder Therapeutic Market, Parkinsons Disease, Generic Share in Parkinsons Disease Market ($m), 2010 and 2017 114
Figure 73: CNS Disorder Therapeutic Market, Parkinsons Disease, Annual Cost of Treatment ($), 2002-2017 115
Figure 74: CNS Disorder Therapeutic Market, Parkinsons Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 116
Figure 75: CNS Disorder Therapeutic Market, Parkinsons Disease, Global Market Drivers and Restraints, 2010-2017 118
Figure 76: CNS Disorder Therapeutic Market, Schizophrenia, Treatment Algorithm 120
Figure 77: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2002-2017 121
Figure 78: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2017 122
Figure 79: CNS Disorder Therapeutic Market, Schizophrenia, Generic Share in Schizophrenia Market, 2010 and 2017 123
Figure 80: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 124
Figure 81: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2017 125
Figure 82: CNS Disorder Therapeutic Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 127
Figure 83: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 129
Figure 84: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast($m), 2002-2017 130
Figure 85: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2017 131
Figure 86: CNS Disorder Therapeutic Market, MDD, Generic Share in MDD Market, 2010 and 2017 132
Figure 87: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2017 133
Figure 88: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Pattern (Thousand), 2002-2017 134
Figure 89: CNS Disorder Therapeutic Market, MDD, Global Market Drivers and Barriers, 2010-2017 136
Figure 90: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Product Pipeline by Indication (%),2011 138
Figure 91: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Product Pipeline by Clinical Stage of Development (%),2011 139
Figure 92: CNS Disorder Therapeutic Market, Alzheimer\'s Disease, Product Pipeline (%),2011 140
Figure 93: CNS Disorder Therapeutic Market, ADHD, Product Pipeline (%), 2011 150
Figure 94: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline (%),2011 153
Figure 95: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline (%),2011 155
Figure 96: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline (%),2011 157
Figure 97: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline (%), 2011 161
Figure 98: CNS Disorder Therapeutic Market, MDD, Product Pipeline (%),2011 163
Figure 99: CNS Disorder Therapeutic Market, Migraine, Product Pipeline (%), 2011 167
Figure 100: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline (%), 2011 169
Figure 101: CNS Disorder Therapeutic Market, Parkinsons Disease, Product Pipeline (%), 2011 175
Figure 102: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline (%), 2011 182
Figure 103: CNS Disorder Therapeutic Market, Global Top Companies Share (%), 2010 198
Figure 104: CNS Disorder Therapeutic Market, SWOT Analysis of Eli Lilly, 2010 199
Figure 105: CNS Disorder Therapeutic Market, SWOT Analysis of Pfizer, 2010 200
Figure 106: CNS Disorder Therapeutic Market, SWOT Analysis of AstraZeneca, 2010 201
Figure 107: CNS Disorder Therapeutic Market, SWOT Analysis of Johnson & Johnson, 2010 202
Figure 108: CNS Disorder Therapeutic Market, SWOT Analysis of Teva 203
Figure 109: CNS Disorder Therapeutic Market, Global M&A Deals by Region, 2010-2011 204
Figure 110: CNS Disorder Therapeutic Market, Global M&A Deals by Indication, 2010-2011 205
Figure 111: CNS Disorder Therapeutic Market, Global, M&A Deals by Value ($m), 2010-2011 206
Figure 112: CNS Disorder Therapeutic Market, Licensing Deals, by Indication, 2010-2011 212
Figure 113: CNS Disorder Therapeutic Market, Co-developments by Indication, 2010-2011 218
Figure 114: GBI Research Market Forecasting Model 228

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *